Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • Aaron M Drucker - , University of Toronto, Women's College Hospital (First author)
  • Chantel Walwyn - , Women's College Hospital (Author)
  • Cherry Chu - , Women's College Hospital (Author)
  • Zenas Z N Yiu - (Author)
  • Bram Rochwerg - (Author)
  • Sonya Di Giorgio - (Author)
  • Bernd W M Arents - (Author)
  • Tanya Mohan - (Author)
  • Tim Burton - (Author)
  • Phyllis I Spuls - (Author)
  • Jochen Schmitt - , Center for Evidence-Based Healthcare (Author)
  • David Prieto-Merino - (Author)
  • Carsten Flohr - (Last author)

Abstract

Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.

Details

Original languageEnglish
Pages (from-to)548-552
Number of pages5
JournalBritish Journal of Dermatology
Volume193
Issue number3
Publication statusPublished - 1 Sept 2025
Peer-reviewedYes

External IDs

PubMedCentral PMC12360034
Scopus 105013812643

Keywords